Your browser doesn't support javascript.
loading
Dystrophin levels and clinical severity in Becker muscular dystrophy patients.
van den Bergen, J C; Wokke, B H; Janson, A A; van Duinen, S G; Hulsker, M A; Ginjaar, H B; van Deutekom, J C; Aartsma-Rus, A; Kan, H E; Verschuuren, J J.
Afiliação
  • van den Bergen JC; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
  • Wokke BH; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
  • Janson AA; Prosensa Therapeutics B.V., Leiden, The Netherlands.
  • van Duinen SG; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Hulsker MA; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Ginjaar HB; Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • van Deutekom JC; Prosensa Therapeutics B.V., Leiden, The Netherlands.
  • Aartsma-Rus A; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Kan HE; Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Verschuuren JJ; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
J Neurol Neurosurg Psychiatry ; 85(7): 747-53, 2014 Jul.
Article em En | MEDLINE | ID: mdl-24292997
ABSTRACT

OBJECTIVE:

Becker muscular dystrophy (BMD) is characterised by broad clinical variability. Ongoing studies exploring dystrophin restoration in Duchenne muscular dystrophy ask for better understanding of the relation between dystrophin levels and disease severity. We studied this relation in BMD patients with varying mutations, including a large subset with an exon 45-47 deletion.

METHODS:

Dystrophin was quantified by western blot analyses in a fresh muscle biopsy of the anterior tibial muscle. Disease severity was assessed using quantitative muscle strength measurements and functional disability scoring. MRI of the leg was performed in a subgroup to detect fatty infiltration.

RESULTS:

33 BMD patients participated. No linear relation was found between dystrophin levels (range 3%-78%) and muscle strength or age at different disease milestones, in both the whole group and the subgroup of exon 45-47 deleted patients. However, patients with less than 10% dystrophin all showed a severe disease course. No relation was found between disease severity and age when analysing the whole group. By contrast, in the exon 45-47 deleted subgroup, muscle strength and levels of fatty infiltration were significantly correlated with patients' age.

CONCLUSIONS:

Our study shows that dystrophin levels appear not to be a major determinant of disease severity in BMD, as long as it is above approximately 10%. A significant relation between age and disease course was only found in the exon 45-47 deletion subgroup. This suggests that at higher dystrophin levels, the disease course depends more on the mutation site than on the amount of the dystrophin protein produced.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distrofina / Distrofia Muscular de Duchenne Limite: Adult / Aged / Humans / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distrofina / Distrofia Muscular de Duchenne Limite: Adult / Aged / Humans / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article